Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676765 · ClinicalTrials.gov registry record · Phase 3
Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy
A Phase 3 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT02676765: Clinical Trial Phase 3 study, sponsored by Virginia Commonwealth University.
NCT02676765 is a Phase 3 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 58 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02676765, a Phase 3 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.
Primary Outcome
Change in the dose of allergen eliciting a wheal 3 mm greater than negative control upon skin prick testing (PC3)
Interventions
- DRUG Placebo tablet
- DRUG allergen extract tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-01-18 |
| Phase | Phase 3 |
Why NCT02676765 stopped before completion
NCT02676765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT02676765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02676765 about?
NCT02676765 is a clinical study titled "Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy". The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.
What is the current status of trial NCT02676765?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2016-06. Estimated completion is 2018-01-18.
What interventions are being tested in trial NCT02676765?
The interventions under investigation include: Placebo tablet (DRUG), allergen extract tablet (DRUG).
Who is sponsoring clinical trial NCT02676765?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02676765's enrollment target sits among peer trials
58 1825th of 2000 higher than 174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia